Browsing: Pharmaceuticals

Aug. 04, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences

— Management to host conference call to discuss second quarter 2026 financial results and business update today at 8:00 a.m. ET —

Agios PharmaceuticalsAGIOreported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company continued the U.S. thalassemia launch of AQVESME and prepared for a potential sickle cell disease approval later this year

Eton Pharmaceuticals (ETON) drew fresh attention after its stock climbed 13.8% on strong trading volume, with interest centering on its commercial rare disease portfolio and late-stage candidates such as Amglidia and the Zeneo hydrocortisone autoinjector

This is a paid press release. Contact the press release distributor directly with any inquiries.

NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ –Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company’s common stock. The dividend will be payable on July 31, 2026, to…

This is a paid press release. Contact the press release distributor directly with any enquiries.

WASHINGTON, July 7, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda’s investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), a rare, serious, and progressive inherited neurological disorder. The designation…

The $10 Billion Acquisition Is Set, as Vertex Pharmaceuticals Bets on a New Blue Ocean in Rare Endocrine Diseases | NAI 500